Prelude Therapeutics 

Quarterly Financials

Values in thousands2026-03-312025-12-312025-09-302025-06-30
Revenue
$4,580
$5,640
$6,500
$0
Gross Profit
4,189
5,640
6,500
-433
EBITDA
-9,994
-16,039
-19,300
-30,798
EBIT
-10,385
-16,457
-19,725
-31,231
Net Income
-10,385
-16,457
-19,725
-31,231
Net Change In Cash
4,580
5,640
6,500
0
Free Cash Flow
-21,685
23,119
-19,115
-26,095
Cash
21,756
35,256
47,532
25,752
Basic Shares
82,519
62,953
76,132
75,993

Annual Financials

Values in thousands2025-12-312024-12-312023-12-312022-12-31
Revenue
$12,140
$7,000
$0
$0
Gross Profit
10,429
7,000
-1,169
-3,042
EBITDA
-97,787
-125,401
-120,663
-122,216
EBIT
-99,498
-127,173
-121,832
-123,540
Net Income
-99,498
-127,173
-121,832
-107,336
Net Change In Cash
12,140
7,000
0
0
Free Cash Flow
-56,369
-103,652
-110,576
-86,748
Cash
35,256
12,474
25,291
30,605
Basic Shares
76,956
75,805
60,357
47,371

Earnings Calls

QuarterEPS
2026-03-31
-$0.13
2025-12-31
-$0.20
2025-09-30
-$0.26
2025-06-30
-$0.41